FAS gene polymorphisms (rs3740286 and rs4064) were not associated with pre-eclampsia risk

An Acad Bras Cienc. 2020 Dec 7;92(4):e20200355. doi: 10.1590/0001-3765202020200355. eCollection 2020.

Abstract

Pre-eclampsia results in real risk and significant impact on indicators related to maternal and child health. The only known treatment is delivery of the fetus and placenta. Despite intensive research, the causes of PE remain to be elucidated. It is suggested that pre-eclampsia is caused by a global maternal inflammatory response to a damaged placenta. Besides inflammation, cytotoxic and apoptotic mechanisms are also implicated in the pathogenesis of pre-eclampsia. Considering the importance of apoptosis to pre-eclampsia genesis, the aim of this study was to determine the frequencies of the genotypes for FAS gene polymorphisms (rs3740286 and rs4064) and to associate these with pre-eclampsia development. Women with and without pre-eclampsia were investigated. Accordingly, peripheral blood was collected, and DNA extracted, followed by genotyping using Real-time PCR with hydrolysis probe. The results showed no association between genotypes and pre-eclampsia development for both polymorphisms studied (χ2=3.39; p=.177, for rs3740286 and χ2=0.119; p=.94 for rs4064). Women with familiar history of pre-eclampsia and primiparity showed more probability to develop the condition, by multiple logistic regression analysis (OR=8.61, CI=3.39-21.86, p<0.0001; OR=6.64. CI=2.94-14.99, p<0.0001, respectively). It seems that FAS gene polymorphisms (rs3740286 and rs4064) might not be important candidates for the development of pre-eclampsia.

MeSH terms

  • Child
  • Female
  • Fetus
  • Genotype
  • Humans
  • Placenta
  • Polymorphism, Genetic / genetics
  • Pre-Eclampsia* / genetics
  • Pregnancy
  • fas Receptor* / genetics

Substances

  • FAS protein, human
  • fas Receptor